Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis
To the Editor: Patients with plaque psoriasis might experience a number of inflammatory musculoskeletal problems, which is consistent with a diagnosis of psoriatic arthritis (PsA). 1 A recent study reported that 30% of patients with plaque psoriasis who were evaluated also had a diagnosis of PsA on the basis of rheumatologists' assessments; in addition, 41% of those patients had not been previously given the diagnosis. 2 Plaque psoriasis with PsA is debilitating 3 and significantly affects overall quality of life. 4 It is unclear whether patients with psoriasis and comorbidities, such as PsA, respond to therapy differently than patients with psoriasis and no comorbidities. Effective therapies that can adequately treat patients with and without PsA are needed. Ixekizumab has a high response rate among patients with moderate-to-severe psoriasis 5 and is a suitable treatment for patients with psoriasis and PsA.
We have summarized the 12-week efficacy and safety data of 80 mg ixekizumab given every 2 weeks (with a 160-mg initial dose) on skin involvement (Psoriasis Area Severity Index [PASI] response), joint pain (Visual Analog Scale, only in patients with self-reported PsA), and quality of life (Dermatology Life Quality Index [DLQI] ). The data was taken from an integrated database of patients with moderate-to-severe psoriasis, both with and without self-reported PsA, derived from 3 phase 3 trials: NCT01474512 (UNCOVER-1), NCT01597245 (UNCOVER-2), and NCT01646177 (UNCOVER-3). Psoriasis and self-reported PsA involvement were initially evaluated on the basis of patient responses to the following 4 questions: 1) Is there palmoplantar involvement?; 2) Is there scalp involvement?; 3) Is there fingernail involvement?; and 4) Has the patient been diagnosed with PsA? Only patients randomized to ixekizumab every 2 weeks (the approved induction dosing regimen for moderate-to-severe psoriasis and PsA) were included in this post hoc integrated analysis.
Of the 1169 patients who were randomized to ixekizumab every 2 weeks, ;24% (283/1169) self-reported PsA at baseline. The mean baseline PASI scores for ixekizumab patients with and without PsA involvement were 21.6 and 19.6, respectively (P \.001). Similarly, the mean baseline body surface area values were 29.1 and 26.6 in ixekizumab Change from baseline in total DLQI score over 12 weeks in IXE Q2W patients with plaque psoriasis, by PsA involvement. Comparisons between groups were based on the Cochrane-Mantel-Haenszel test stratified by study. *P \.05, IXE Q2W patients with PsA versus without PsA. DLQI, Dermatology Life Quality Index; IXE Q2W, ixekizumab 80 mg every 2 weeks; PsA, psoriatic arthritis. patients with and without PsA involvement, respectively (P \.05).
Improvements from baseline in PASI 75, PASI 90, and PASI 100 were observed in both groups with and without PsA involvement (Fig 1) . No significant differences between groups were observed at any time point for any PASI response.
Among patients who self-reported PsA at baseline (n ¼ 283), the mean joint pain Visual Analog Scale score at baseline was 47.4. The mean change from baseline in joint pain Visual Analog Scale significantly improved at week 1 (least squares mean [LSM] change, À13.1; P \.001) and continued to improve up to week 12 (LSM change, À26.8; P \.001; data not shown).
The total mean change in DLQI score from baseline also improved in all patients, regardless of PsA involvement (Fig 2) . Mean DLQI scores at baseline were 14.3 and 12.3 for patients with and without PsA, respectively (P \.001). Compared with patients with PsA, significantly greater improvements from baseline in DLQI were observed at weeks 2 (LSM change, À6.9 vs À7.5) and 4 (LSM change, À8.6 vs À9.2) in patients without PsA (P \.05). These statistical differences in DLQI scores at weeks 2 and 4 are not considered clinically meaningful. No significant difference between patients with and without PsA in total mean change from baseline in DLQI score at week 12 was observed (Fig 2) .
Infections were commonly reported (27.0%) among all patients, regardless of PsA involvement. The incidences of cerebrocardiovascular events, malignancies, and inflammatory bowel disease were low (\0.5%) in patients with and without PsA. No deaths were reported in the 12-week induction phases of these studies.
Our findings demonstrated that regardless of patients' PsA status at baseline, ixekizumab every 2 weeks was effective and improved health measures over a 12-week treatment period. Adverse events were minimal. Consistent with a previous report that suggested that PsA involvement does not significantly affect treatment response to biologic therapy, 6 our analysis demonstrated that PsA involvement did not appear to modulate the efficacy of ixekizumab given every 2 weeks in treating psoriasis. 
